Decoy oligodeoxynucleotide technology: an emerging paradigm for breast cancer treatment

Mahjoubin‐Tehran, Maryam; Rezaei, Samaneh; Jalili, Amin; Aghaee‐Bakhtiari, Seyed Hamid; Sahebkar, Amirhossein

doi:10.1016/j.drudis.2019.10.008

Cited by 12 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gene therapy based on the applications of ODNs provides an alternative to existing therapeutic approaches for the prevention/treatment of various pathological conditions namely, renal diseases [83], cancers [84,85], cystic fibrosis (CF) [86], asthma and COPD [87]. Recent advances in the fields of molecular and cellular biology have made it possible to transfer target genes of interest into somatic cells.…”

Section: Decoy Oligonucleotidesmentioning

confidence: 99%

Recent trends of NFκB decoy oligodeoxynucleotide-based nanotherapeutics in lung diseases

Mehta

Paudel

Shukla

et al. 2021

Journal of Controlled Release

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Decoy Oligonucleotidesmentioning

confidence: 99%

Recent trends of NFκB decoy oligodeoxynucleotide-based nanotherapeutics in lung diseases

Mehta

Paudel

Shukla

et al. 2021

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…Due to the specificity, finding the best sequence of TF binding sites for regulation of the target gene expression is one of the technical obstacles of this method [ 31 ]. The use of decoy ODNs as a therapeutic tool has been established for many years for various diseases including cancers [ 32 ]. Decoy transfection is a promising tool for inhibition of gene activation.…”

Section: Decoymentioning

confidence: 99%

Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis

Mahjoubin‐Tehran

Teng

Jalili

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) have been classified into several types of disease, of which atherosclerosis is the most prevalent. Atherosclerosis is characterized as an inflammatory chronic disease which is caused by the formation of lesions in the arterial wall. Subsequently, lesion progression and disruption ultimately lead to heart disease and stroke. The development of atherosclerosis is the underlying cause of approximately 50% of all deaths in westernized societies. Countless studies have aimed to improve therapeutic approaches for atherosclerosis treatment; however, it remains high on the global list of challenges toward healthy and long lives. Some patients with familial hypercholesterolemia could not get intended LDL-C goals even with high doses of traditional therapies such as statins, with many of them being unable to tolerate statins because of the harsh side effects. Furthermore, even in patients achieving target LDL-C levels, the residual risk of traditional therapies is still significant thus highlighting the necessity of ongoing research for more effective therapeutic approaches with minimal side effects. Decoy-based drug candidates represent an opportunity to inhibit regulatory pathways that promote atherosclerosis. In this review, the potential roles of decoys in the treatment of atherosclerosis were described based on the in vitro and in vivo findings.

show abstract

“…This is the premise of decoy base therapy where the drug candidates represent an opportunity to inhibit a known activated regulatory pathway that promotes CVD. Decoy technology includes two main approaches, decoy ODN and decoy peptides [9,10].…”

Section: Decoysmentioning

confidence: 99%

“…Transcription factors, as trans-regulatory elements, regulate gene transcription by binding to the cis-element [11]. Decoy ODNs have a similar structure to the cis-element of the target gene and trap the transcription factor and modulate the gene expression (Figure 2A) [9].…”

Section: Decoysmentioning

confidence: 99%

“…Additionally, the application of decoys for the treatment of cancer, another major global health problem, has been investigated. Reports for the usage of decoy ODN for reducing the expression of target genes including ER, CRE, STAT3, and Sp1 have shown potential therapeutic utility in breast cancer therapy [9]. It has also been shown that peptide decoys have a potential therapeutic effect for cancers such as breast cancer [10], bladder cancer [15], colon cancer [16], lung cancer [17], liver cancer [18], and prostate cancer [19].…”

Section: Therapeutic Potential Of Decoysmentioning

confidence: 99%

See 1 more Smart Citation

Harnessing the Therapeutic Potential of Decoys in Non-Atherosclerotic Cardiovascular Diseases: State of the Art

Mahjoubin‐Tehran

Atkin

Bezsonov

et al. 2021

JCDD

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the main cause of global death, highlighting the fact that conventional therapeutic approaches for the treatment of CVD patients are insufficient, and there is a need to develop new therapeutic approaches. In recent years, decoy technology, decoy oligodeoxynucleotides (ODN), and decoy peptides show promising results for the future treatment of CVDs. Decoy ODN inhibits transcription by binding to the transcriptional factor, while decoy peptide neutralizes receptors by binding to the ligands. This review focused on studies that have investigated the effects of decoy ODN and decoy peptides on non-atherosclerotic CVD.

show abstract

Decoy oligodeoxynucleotide technology: an emerging paradigm for breast cancer treatment

Cited by 12 publications

References 25 publications

Recent trends of NFκB decoy oligodeoxynucleotide-based nanotherapeutics in lung diseases

Recent trends of NFκB decoy oligodeoxynucleotide-based nanotherapeutics in lung diseases

Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis

Harnessing the Therapeutic Potential of Decoys in Non-Atherosclerotic Cardiovascular Diseases: State of the Art

Contact Info

Product

Resources

About